Harnessing Novel Targets and GLP Combination Therapies to Improve Efficacy and Tolerability for Longer Lasting Clinical Outcomes

Time: 8:00 AM – 4:10 PM

Venue Details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Alessandro Pocai, Senior Director – Cardiovascular, Metabolism, PH and Retinal Research, Scientific Strategy and Innovation, Johnson and Johnson, Brandy Bennett, Head Of Obesity Strategy and Business Operations, Regeneron, Charlie Harris, Associate Vice President, Eli Lilly, Evan Frary, Head of Medical Affairs, Zealand, Faraz Naqvi, Medical Director, Ambrosia Biosciences, Hariprasad Vankayalapati, Chief Scientific Officer, Biolexis, Jay Caplan, Founder and President, Fractyl Therapeutics, Jay Olson Biotechnology, Equity Research Analyst, Oppenheimer and Co., Jill Kompa, Senior Global Program Regulatory Director, RA lead Cardiovascular-Metabolism, Novartis, Jingyu Julia Luan, Executive Regulatory Science Director, AstraZeneca, John Suschak, Senior Director, Translational Science, Altimmune, Laurent Audoly, Chief Executive Officer, Prive Bio, Leigh MacConell, Chief Development Officer, High Tide Therapeutics, Linda Sasset, Senior Scientist, RenBio, Mafalda Pereira, Lab Head and Senior Scientist, Boehringer Ingelheim, Martin Brenner, Chief Executive and Chief Scientific Officer, iBio, Rahul Dhanda, Co-Founder and Chief Executive Officer, Syntis Bio, Robert Gabbay, Chief Medical Officer and Senior Vice President at Joslin Diabetes Center and Associate Professor of Medicine, Harvard University, Sharath Hedge, Chief Scientific Officer, Congruence Therapeutics, Steven Dickman, Founder and Chief Executive Officer, CBT Advisors, Teo Uysal, Chief Executive Officer, ERX Pharmaceuticals, Yajing Zhu, Head of Real World Science: Obesity and Liver, Novo Nordisk